Navigation Links
VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
Date:5/25/2011

e indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the QNEXA End-of-Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's QNEXA CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the QNEXA MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL on QNEXA or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety conc
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
11. VIVUS to Present at the 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... July 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ... field of regenerative medicine, announced today that it ... to investors on Tuesday, July 29, 2014, at ... will include an overview of Asterias, business strategy ... visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes ...
(Date:7/24/2014)... yet to materialise. Yet, scientists are making progress ... faster. One such approach relies on quantum dotsa ... an electric field. A new study demonstrates that ... dots (TQDs) with electrical impulses can help better ... TQDs be used as quantum information units, which ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Reaches severance agreement with unionsSEATTLE, May 15 Cell ... that, as previously discussed in a press release on ... operations and has reached agreement with the employee union ... a reduction of CTI,s total headcount in Italy by ...
... (TSX:ONC, NASDAQ: ONCY ) announced today that data from ... at the 2009 American Society of Clinical Oncology (ASCO) Annual ... 29-June 2, 2009. The abstracts are available on the ASCO ... poster presentations, - Dr. Monica ...
... May 14 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc., (TSX: SDI), ... and a therapeutic targeting severe sepsis, today announced its ... 2009. , "This quarter, we achieved an important milestone ... Toraymyxin(TM) for the US market after thorough due diligence ...
Cached Biology Technology:Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses 2Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference 2Spectral announces first quarter 2009 results 2Spectral announces first quarter 2009 results 3Spectral announces first quarter 2009 results 4Spectral announces first quarter 2009 results 5Spectral announces first quarter 2009 results 6Spectral announces first quarter 2009 results 7
(Date:7/25/2014)... July 25, 2014 In the first broad-scale estimate of ... scientists and collaborators calculated that trees are saving more ... incidences of acute respiratory symptoms. , While trees, pollution ... less than 1 percent, the impacts of that improvement ... the reduced air pollution at nearly $7 billion every ...
(Date:7/25/2014)... of people lived on the land now called California, ... the availability of plants they used for food, fuel, ... to maintain desired habitat and natural resources. , Frank ... Southwest Station, will lead a field trip ... Ecological Society of America,s 99th Annual Meeting, in Sacramento, ...
(Date:7/25/2014)... scars on this false-color image from the Terra satellite show ... rash of wildfires in Eastern Russia. The burn scars ... background. The wildfires have broken across the remote parts ... this false-color image from the MODIS instrument, it is ... that continue. Two recent image features noted below show the ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... noses and Microsoft Windows, infamous blue screen of death ... being made by a new research report appearing online ... Specifically, scientists now know exactly why we sneeze, what ... not work properly. Much like a temperamental computer, our ...
... Olympic athletes may be the best trained and physically ... susceptible to back pain. BackPainRelief.net is releasing an infographic ... injuries can be avoided. (Photo: ... for a number of injuries, and back pain is ...
... (July 30, 2012) When the longest cells in the body ... is no easy task. This is in part because these ... one meter in adult humans which is a lot ... order to reach the "command center" of the cell,s nucleus. ...
Cached Biology News:Allergies? Your sneeze is a biological response to the nose's 'blue screen of death' 2Backpainrelief.net Tackles Sports Injuries with Infographic 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3
... to Dideoxycytidine Dideoxycytidine is a cytidine analog ... inhibiting retroviral activity. Immunogen: Chemical ... Specificity: The specificity of the ddC antiserum ... moles of ddC to moles of ddC analog ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... is designed with a variety of motion ... all in one unit. Shake, rock, roll ... compartments allow for hybridization and blotting procedures ... , The upper chamber uses a roller ...
... Concentrator, the SPD series takes the 'Classic' ... twist., The SPD121P SpeedVac comes equipped with ... runs; preventing samples from freezing; and allowing ... end-users preset level., Standard features on the ...
Biology Products: